CoreCap Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

CoreCap Advisors’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$135K	Buy	428 +425	+14,167%	+$100K	﹤0.01%	1002
2026 Q1	$599	Hold	3	–	–	﹤0.01%	2624
2025 Q4	$567	Buy	+3	New	+$576	﹤0.01%	2686

Other funds holding LGND

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

Woodstock Corp Boston, Massachusetts $1.2B AUM 26.37% 1-Year Est. Return

Moody National Bank Trust Division Galveston, Texas $1.21B AUM 38.93% 1-Year Est. Return

Handelsbanken Fonder

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Linden Thomas Advisory Services Charlotte, North Carolina $1.24B AUM 47.37% 1-Year Est. Return

Tealwood Asset Management Minneapolis, Minnesota $261M AUM 52.68% 1-Year Est. Return

Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return

Portside Wealth Group Provo, Utah $858M AUM 26.82% 1-Year Est. Return

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

CoreCap Advisors's LGND Position: Q2 2026 in Review

CoreCap Advisors increased its Ligand Pharmaceuticals (LGND) stake by 14,167% in Q2 2026, buying an estimated $100K and bringing the position to 428 shares worth $135K. The position accounts for ﹤0.01% of the portfolio, ranked #1002.

CoreCap Advisors first reported a position in LGND in Q4 2025 and has held it in 3 quarters since. 36 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

CoreCap Advisors held 428 shares of Ligand Pharmaceuticals worth $135K as of Q2 2026.
CoreCap Advisors bought 425 Ligand Pharmaceuticals shares in Q2 2026, an estimated $100K.
Ligand Pharmaceuticals made up ﹤0.01% of CoreCap Advisors's portfolio in Q2 2026, its #1002 holding.
CoreCap Advisors first reported a position in Ligand Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
36 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.